Manufacturer
BAXTER ONCOLOGY GMBH
Contents
Ifosfamide
Indication
Inoperable malignant tumours that are sensitive to ifosfamide eg bronchial carcinoma, ovarian carcinoma, testicular tumours, soft-tissue sarcoma, breast cancer, pancreatic carcinoma, hypernephroma, endometrial carcinoma, malignant lymphomas.
Instruction
Holoxan should only be administered by an experienced oncologist. The dosage must be adapted to each patient individually. In single-drug therapy of adults, the most common treatment is based on fractionated doses.
Drug interaction
Neurotoxicity, hematotoxicity & nephrotoxicity may be increased by prior cisplatin therapy. Increased hypoglycemic effects w/ sulfonylureas. Increased bone marrow depression w/ allopurinol. Disturbances of anticoagulant control of warfarin.
Malaysia
